Search results

Technologies 36

View all

• GC Therapeutics: Changing the Future of Cell Therapies
  GC Therapeutics (GCTx) is applying their stem cell-engineering TFome platform to overcome barriers in the development and manufacturing of cell therapies to improve patient access across a broad range of disease areas.
• Instrument-Free Molecular Diagnostics
  A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings.
• AminoX: Making Better Protein Drugs, Quicker and Cheaper
  AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition.
• Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
  eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance.
• Ichor: Reversing Aging
  Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health.
• Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
  This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers.

Collaborations 1

• Brigham-Wyss DxA
  The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests.

News 256

View all

• Press Release
  
  Wyss Institute at Harvard University launches its Diagnostics for Human and Planetary Health platform headed by David Walt
  February 10, 2025
• Press Release
  
  Wyss Institute launches Healthy Aging Fund with a gift from The Colossal Foundation
  January 30, 2025
• Community
  
  Li Li on Bringing Advanced Omics Technology to Dermatology
  January 28, 2025

Multimedia 74

View all

• 

  Video/Animation
  The End of Aging—And Extinction | George Church, Ph.D. on Longevity, Dire Wolves, and Woolly Mammoths
  What if aging was optional—and extinction reversible? In this episode of Ignition Sequence, Wyss Core Faculty member and geneticist and biotech pioneer, George Church, Ph.D., joins host Dylan Bohbot to explore the frontiers of gene therapy, de-extinction, and the future of human health. A founding scientist behind the Human Genome Project, and co-founder of Colossal...

• 

  Video/Animation
  Finding a Balance In Bipolar Disorder Through Drug Prediction and Organoid-Based Drug Screening
  CircaVent is a high-throughput drug screening platform that combines predictive algorithms, preclinical models, and human brain organoids to efficiently identify and test drugs that could treat the underlying causes of bipolar disorder. CircaVent is initially focused on addressing the circadian rhythm disruptions that are a common hallmark of BD, and could dramatically speed up the...

• 

  Video/Animation
  Human Skin Rejuvenation: Li Li, Ph.D.
  In this episode of Conquer Aging or Die Trying, host Michael Lustgarten, Ph.D. speaks to Wyss Postdoctoral Fellow Li Li, Ph.D. about the technology she’s developing for skin rejuvenation.  

• 

  Video/Animation
  20-ish Questions with George Church
  20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows George Church, a founding Core Faculty member of the Wyss Institute and lead of the Synthetic Biology Focus Area. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  The Dish Live with special guest George Church
  In this very special live taping of “The Dish,” host Johannes Fruehauf sits down with renowned geneticist and Wyss Core Faculty member, George Church, Ph.D. Widely known for discovering the first direct genomic sequencing method, Church has reshaped the world of genetics. A professor at Harvard and MIT and a founding professor at the Wyss...

• 

  Audio/Podcast
  SeqVerify: A New Easily Accessible Tool for Comprehensive Cell Line Quality Assessment – The Stem Cell Report
  During the last decade, advances in genome editing and pluripotent stem cell (PSC) culture have let researchers generate edited PSC lines to study a wide variety of biological questions. However, abnormalities in cell lines such as aneuploidy, mutations, on-target and off-target editing errors, and microbial contamination can arise during PSC culture or due to undesired...